CClinicalTrials.gg
Sign In
CompletedNCT00612885Updated Nov 1, 2013

Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study

An observational study in Osteoarthritis and Arthritis, Rheumatoid, sponsored by Boehringer Ingelheim. Completed at 11 sites in Korea, Republic of. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Observational

Study type
Observational
Enrollment
425
Ages
15 Years and older
Sex
All
01

Study summary

The main objective of this PMS study was to monitor and assess the safety of Mobic® intramuscular injection (7.5mg \~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic® capsule therapy was possible) in Korean patients with osteoarthritis and rheumatoid arthritis.

02

Conditions studied

  • Osteoarthritis
  • Arthritis, Rheumatoid
03

In context

Arthritis

3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.

This study's enrollment of 425 is above the median of 155 across 1,057 observational studies indexed under Arthritis.

Browse Arthritis studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

diagnosed as osteoarthritis and rheumatoid arthritis

Exclusion criteria

EXCLUSION CRITERIA:

  1. Known hypersensitivity to meloxicam
  2. Cross hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs
  3. Symptoms of asthma, rhinitis, angioneurotic edema, or urticaria following the administration of aspirin or other NSAIDs
  4. Active peptic ulceration
  5. Severe hepatic failure.
  6. Non-dialysed severe renal insufficiency
  7. Children and adolescents aged 15 years or less
  8. Pregnancy or breastfeeding
05

Study design

Enrollment
425 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Efficacy assessment by the treating physician

    Time frame: up to 3 day

  2. Combined efficacy, safety and tolerability assessment by the treating physician

    Time frame: up tp 3 day

  3. Incidence of adverse events

    Time frame: up tp 3 day

07

Study locations

11 sites
  • Boehringer Ingelheim Investigational Site
    Busan, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Chungbuk, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Daegu, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Daejeon, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Gangwondo, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Gwangju, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Gyeongbuk, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Gyeonggido, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Gyeongnam, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Jeonnam, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00612885
Lead sponsor
Boehringer Ingelheim
First posted
Feb 12, 2008
Start date
Mar 2004
Primary completion
Aug 2005
Completion
Aug 2005
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · B.I. Korea Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Arthritis→

Other studies from this sponsor

Boehringer Ingelheim

Start the discussion